E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
The 'premenstrual syndrome' is a cyclical condition occurring 7-10 days before the onset of menstruation, and is relieved at, or shortly after commencement of menstrual flow. The most commonly reported symptoms include breast tenderness, bloating and cognitive complaints, such as poor concentration, confusion and forgetfulness, as well as depression, anxiety, irritability, and mood swings. |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine whether St John's Wort is more beneficial than placebo supplements in relieving symptoms of PMS, using both subjective (daily symtpom checklists and self reports of depression, impulsivity, agression and anxiety levels) and objective measures (blood tests to measure hormone, neurotransmitter and cytokine levels, and response bias measures from an emotional Stroop task). |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives include examining the relationship between serotonin levels, cytokine levels and PMS symptoms, determining whether there is a relationship between the use of SJW and both cytokine and serotonin levels and determining whether the symptom profiles of a clinical population are similar to, or differ from, those of self-referred research recruited women |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
To qualify for inclusion in this study, a patient must satisfy all of the criteria listed below:
1. Written informed consent has been obtained prior to enrolment in the study. 2. The participant is female and aged between 18 and 45 years. 3. The participant is of good health, which will be assessed by the clinic doctor. 4. The participant has regular menstrual cycles, with a cycle length of 25-35 days. 5. The participant has PMS defined by at least a 30% increase in symptoms in the luteal phase compared to the follicular phase.
|
|
E.4 | Principal exclusion criteria |
Women will be excluded from the study for any of the following reasons:
1. Taking prescribed medication for PMS. 2. Taking OTC medication for PMS and unwilling to abstain for the duration of the trial. 3. Using hormonal preparations, including oral contraception or Hormone Replacement Therapy (HRT) 4. Is pregnant, planning pregnancy or lactating. 5. Has known photosensitivity. 6. Has depression or anxiety. 7. Taking: • HIV protease inhibitors (indinavir, nelfinavir, ritonavir, saquinavir) • HIV non-nucleoside reverse transcriptase inhibitors (efavirenz, nevirapine) • Warfarin • Cyclosporine • Oral contraceptives • Photoreactive agents • Anticonvulsants (carbamazepine, phenobarbitone, phenytoin) • Digoxin • Theophylline • Triptans (sumatriptan, naratriptan, rizatriptan, zolmitriptan, frovatriptan) • SSRIs (citalopram, fluoxetine, fluvoxamine, paroxetine, sertaline) • Psoralens, (oxsoralen, trisoralen, ciprofloxacin and tetracycline) • Lithium • Antipsychotic drugs • Neuroleptic drugs • Cimetidine • Oral corticosteroids • Thyroid hormones • Immunosuppressive agents.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The endpoint of the trial is the change in total premenstrual symptom scores on the daily PMS symptom checklist, with the secondary endpoints being the change in specific symptoms on the PMS symptom checklist, changes in aggression, impulsivity, depression, anxiety, cytokine, and serotonin levels.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | Information not present in EudraCT |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Information not present in EudraCT |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Information not present in EudraCT |
E.6.7 | Pharmacodynamic | Information not present in EudraCT |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Information not present in EudraCT |
E.6.12 | Pharmacoeconomic | Information not present in EudraCT |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Information not present in EudraCT |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The trial will end when every participant has finished their ninth menstrual cycle, defined by the first day of the tenth bleed. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |